Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Holymoly1269 Feb. 17 at 10:42 PM

$KALA back to $10 lazaar

0 · Reply

ALOSETE Feb. 17 at 9:59 PM

$KALA It’s clear that the legal team is working at full speed.

0 · Reply

ALOSETE Feb. 17 at 9:57 PM

$KALA I’m observing what appears to be a silent accumulation of the current float. I expect a new asset announcement in March, which could lead to a substantial upward move in the stock price.

0 · Reply

EF5Stocks Feb. 17 at 9:49 PM

$KALA Lots of puzzle pieces coming into play here. Seems like a lot of varying parties have a stake. I'm hoping that we start a sustained and slow uptrend soon. It has been difficult to discern whether the sell pressure here is intrinsic to this stock or just a function of the very weak and volatile market.

0 · Reply

ALOSETE Feb. 17 at 9:43 PM

$KALA Reverse Merger every day more near. All in process.

0 · Reply

MrTicker Feb. 17 at 9:22 PM

$KALA new 13G filed today. Form SCHEDULE 13G/A KALA BIO, Inc. Filed by: BAKER BROS. ADVISORS LP 10K WIZARD 3:21 PM ET 2/17/2026 http://archive.fast-edgar.com/20260217/ANBZI22C8C22O9ZU222S2ZZZUCBTZ2V2ZB82 Filed on: February 17, 2026

0 · Reply

OfficialStocktwitsUser Feb. 17 at 6:01 PM

$KALA RSI: 26.34, MACD: -0.0720 Vol: 0.09, MA20: 0.50, MA50: 0.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TwongStocks Feb. 17 at 4:39 PM

$KALA $INDP $MYNZ I just realized that Lazar resigned last week as CEO of KALA (he's still on their board) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479419/000182912626000995/kalabio_8k.htm

0 · Reply

ALOSETE Feb. 17 at 4:33 PM

$KALA something is cooking.

0 · Reply

ALOSETE Feb. 17 at 3:22 PM

$KALA $INDP $MYNZ This large number of clean shells for Lazar tell you he has many assets to merger. I think Kala will be the firts.

1 · Reply

KALA BIO Settles Approximately $10.6 million of Debt

Dec 4, 2025, 10:45 AM EST - 2 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 29, 2025, 12:00 PM EDT - 5 months ago

Why Is Eye Disease Focused Kala Bio Stock Plunging On Monday?

Aug 8, 2025, 8:00 AM EDT - 6 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 6 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 9, 2025, 8:00 AM EDT - 7 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

May 29, 2025, 8:00 AM EDT - 9 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 2 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 2 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 19, 2023, 7:12 AM EST - 3 years ago

Kala Pharma: Rare Eye Disease Biotech Lottery Ticket Based On Stem Cell Platform

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 29, 2022, 8:30 AM EST - 3 years ago

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 12, 2022, 7:51 PM EDT - 3 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 7:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 10:17 AM EDT - 4 years ago

Why Kala Pharmaceuticals Shares Are Rising Today

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 10:54 AM EDT - 4 years ago

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 9, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 2, 2022, 1:25 PM EDT - 4 years ago

Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

May 1, 2022, 9:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Holymoly1269 Feb. 17 at 10:42 PM

$KALA back to $10 lazaar

0 · Reply

ALOSETE Feb. 17 at 9:59 PM

$KALA It’s clear that the legal team is working at full speed.

0 · Reply

ALOSETE Feb. 17 at 9:57 PM

$KALA I’m observing what appears to be a silent accumulation of the current float. I expect a new asset announcement in March, which could lead to a substantial upward move in the stock price.

0 · Reply

EF5Stocks Feb. 17 at 9:49 PM

0 · Reply

ALOSETE Feb. 17 at 9:43 PM

$KALA Reverse Merger every day more near. All in process.

0 · Reply

MrTicker Feb. 17 at 9:22 PM

0 · Reply

OfficialStocktwitsUser Feb. 17 at 6:01 PM

0 · Reply

TwongStocks Feb. 17 at 4:39 PM

$KALA $INDP $MYNZ I just realized that Lazar resigned last week as CEO of KALA (he's still on their board) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479419/000182912626000995/kalabio_8k.htm

0 · Reply

ALOSETE Feb. 17 at 4:33 PM

$KALA something is cooking.

0 · Reply

ALOSETE Feb. 17 at 3:22 PM

$KALA $INDP $MYNZ This large number of clean shells for Lazar tell you he has many assets to merger. I think Kala will be the firts.

1 · Reply

TwongStocks Feb. 17 at 2:53 PM

David Lazar has been pretty busy recently. Dec 2025: Enters into a $6M securities purchase agreement with $KALA. Lazar appointed KALA's CEO & Chairman of the Board. Dec 2025: Enters into a $6M securities purchase agreement with $INDP. Lazar appointed INDP's Co-CEO & Chairman of the Board. Feb 2026: Enters into a $6M securities purchase agreement with $MYNZ. Lazar appointed MYNZ's Chairman of the Board. Wonder what his plans are for these companies.

0 · Reply

VoidGorilla Feb. 16 at 10:24 PM

$KALA $XCH.X $RCEL $APUS ))())

0 · Reply

VoidGorilla Feb. 15 at 8:44 PM

$KALA $RCEL $APUS $AGPU 6<><

0 · Reply

EF5Stocks Feb. 14 at 11:39 PM

$KALA This is clearly a merger/pivot play but for the short term, nice bullish engulfing candle on Friday on slightly higher volume over Thursday's session.....is the bottom @ .35 in? Bullish Engulfing is not a surefire thing but has approximately 60% accuracy from what I recall. We'll see what next weeks brings.

0 · Reply

_MihawkSwings Feb. 14 at 6:49 PM

OLB 💎 What a close! Next week is going to be big here. Make sure to keep OLB on ur watch if u haven't added, Upcoming catalyst- DMINT spint off . ✅ Pennies have been hot and I believe we continue the trend into next week as well. OLB has the look and Setup to see a parabolic move from here on. . $1+ potential. $KALA $APUS $ELOG $LUCY watching

1 · Reply

Bigdubs Feb. 13 at 10:14 PM

$KALA Ok today I will go over the Cap table and the outstanding shares these are the shares that comprise of the float. *NOTE these are not publicly trading but will enter over time and after news. I will be long gone before they enter.* Fallow the money... Still another near million AAA preferred shares that need to find a home. Current best guess on the asset, Canadian Data Center Buildout... That's only a guess and I maybe wildly off.

0 · Reply

EF5Stocks Feb. 13 at 6:25 PM

$KALA Has anyone ever spoken to Lazar? I know he cannot disclose anything specific but has anyone gotten a feel for his plans for $KALA or his approach more generally? I am surprised there hasn't been any kind of PR here to at least update the market on all of the filings (yes, I know folks can do their own DD but it might still be helpful).

2 · Reply

Holymoly1269 Feb. 13 at 6:03 PM

$KALA lazar stock bull

0 · Reply

ALOSETE Feb. 13 at 5:43 PM

$KALA Nice accumulation.

0 · Reply

ItsAllAboutBeingFirst Feb. 13 at 4:30 PM

$CRIS $IBB $KALA $XBI man that trade looks food on cris - was staring you in the face the whole time

0 · Reply

Jjjjen Feb. 13 at 3:59 PM

$KALA i'm in at .66 ...sigh...has it been bottomed yet ?

1 · Reply

dannosmith Feb. 13 at 2:12 AM

$KALA I hate to say i told you so.....rhis stock is a 🐶

0 · Reply

Market Cap	4.00M
Revenue (ttm)	0.00
Net Income (ttm)	-38.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-3.28

Volume	634,500
Avg Vol	5,719,862
Day's Range	N/A - N/A
Shares Out	9.83M
Stochastic %K	27%
Beta	-2.43
Analysts	Hold
Price Target	$1.50